Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 110590102 | 11059010 | 2 | F | 20150413 | 20160627 | 20150423 | 20160704 | EXP | US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2015-025490 | BRISTOL MYERS SQUIBB | 71.94 | YR | M | Y | 0.00000 | 20160704 | PH | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 110590102 | 11059010 | 1 | PS | SPRYCEL | DASATINIB | 1 | Oral | 100 MG, QD | 21986 | 100 | MG | QD | |||||||
| 110590102 | 11059010 | 2 | SS | SPRYCEL | DASATINIB | 1 | Oral | 50 MG, QD | 21986 | 50 | MG | QD |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 110590102 | 11059010 | 1 | Chronic myeloid leukaemia |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 110590102 | 11059010 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 110590102 | 11059010 | Decreased appetite | |
| 110590102 | 11059010 | Myocardial infarction | |
| 110590102 | 11059010 | Pulmonary oedema |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 110590102 | 11059010 | 1 | 20150321 | 0 | ||
| 110590102 | 11059010 | 2 | 20160320 | 0 |